COMMUNIQUÉS West-GlobeNewswire
-
Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update
16/11/2026 -
ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update
16/11/2026 -
Commure Acquires Elaborate to Cure the Clinician Inbox
16/11/2026 -
Iambic Provides Business Updates and Third Quarter 2026 Financial Results
16/11/2026 -
Enlivex Announces Pricing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
16/11/2026 -
Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel
16/11/2026 -
Cannara to Announce Fiscal Q4 and Fiscal Year 2026 Financial Results on November 30, 2026
16/11/2026 -
Cannara annoncera ses résultats financiers du quatrième trimestre et de l'exercice 2026 le 30 novembre 2026
16/11/2026 -
Nasus Pharma Appoints Nir Sassi as Chief Financial Officer
16/11/2026 -
Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update
16/11/2026 -
Radiopharm Theranostics Presents Interim Analysis from Phase 2b Imaging Study of RAD101 in Suspected Recurrent Brain Metastases Following Radiotherapy at the Society for Neuro-Oncology Annual Meeting
16/11/2026 -
MacuMira Receives CE Mark for Its Microcurrent Treatment for Dry AMD
16/11/2026 -
Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts
16/11/2026 -
Davion Healthcare Plc Agrees to Terms in Acquisition of Independence Care Homecare Network
16/11/2026 -
AVITA Medical Reports Complete Cohealyx I Data in Full-Thickness Wounds Showing Earlier Graft Readiness and Six-Month Healing Outcomes
16/11/2026 -
Rakovina Therapeutics to Present ATR Inhibitor Data in PTEN-Deficient Prostate Cancer at the 38th EORTC-NCI-AACR Symposium
16/11/2026 -
Vivani Medical Announces Private Placement Equity Financing
16/11/2026 -
Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
16/11/2026 -
Arexera Therapeutics Highlights Potentially Best-in-Class Preclinical Profile and Initiates Clinical Development for ATL-101 in Huntington’s Disease
16/11/2026
Pages